Výsledky vyhledávání - "Sara Broering"

Flavopiridol Can Be Safely Dose Escalated in Relapsed CLL Patients: Achievement of Target Cmax Results in Improved Clinical Activity

Autor: Dimitrios Colevas, James T. Dalton, Thomas S. Lin, Sara Broering, Michelle B. McEldowney, Beth Fischer, Kristie A. Blum, Mollie E. Moran, Mitch A. Phelps, John C. Byrd, Michael R. Grever

Publikováno v: Blood. 108:2845-2845

Background: Flavopiridol induces p53-independent apoptosis in CLL cells in vitro. Clinical studies using 24–72-hr continuous IV infusion (CIVI) schedules showed little activity, due to increased drug binding to human plasma proteins and inadequate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f2c0c740b86705ec7ccb88fd72b1ddf0
https://doi.org/10.1182/blood.v108.11.2845.2845

Zobrazit plný text záznamu

Flavopiridol Is Active in Genetically High-Risk, Relapsed Chronic Lymphocytic Leukemia (CLL): Analysis of 56 Patients by Cytogenetic Abnormality

Autor: Mollie E. Moran, Thomas S. Lin, Sara Broering, Michelle B. McEldowney, Dimitrios Colevas, Nyla A. Heerema, Michael R. Grever, Gerard Lozanski, Beth Fischer, John C. Byrd, Kristie A. Blum

Publikováno v: Blood. 108:302-302

Background: Treatment options for relapsed CLL patients (pts) with high-risk genetic features, such as del(17p13) or a complex karyotype, are limited. Flavopiridol induces p53-independent apoptosis in CLL cells in vitro, but increased drug binding to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b7de83f930f4479ec5a968328b89d115
https://doi.org/10.1182/blood.v108.11.302.302

Zobrazit plný text záznamu

Successful Management (Mgt) of Hyperkalemia Associated with Tumor Lysis Syndrome (TLS) in Refractory Chronic Lymphocytic Leukemia (CLL) Patients (pts) Receiving Flavopiridol on an Active Pharmacologically Derived Schedule

Autor: John C. Byrd, Kristie A. Blum, Michael R. Grever, Beth Fischer, Mollie E. Moran, Sara Broering, Thomas S. Lin, Michelle Brooker-McEldowney

Publikováno v: Blood. 106:2124-2124

Introduction: Flavopiridol, a synthetic flavone with marked clinical efficacy in refractory high risk CLL, can cause overwhelming TLS with hyperkalemia. Accrual to a National Cancer Institute (NCI) sponsored phase 1 trial of flavopiridol (NCI 5746) w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5d1fc6110862dd4526581b5930cba22f
https://doi.org/10.1182/blood.v106.11.2124.2124

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání